Endometrial Cancer Deaths Rise 1.6% Annually as Obesity Drives Younger Cases
New JAMA review reveals alarming trends in endometrial cancer: rising mortality rates and increasing cases in women under 40.
Summary
A comprehensive JAMA review reveals concerning trends in endometrial cancer, the fourth most common cancer in US women. Mortality rates increased 1.6% annually from 2014-2023, while incidence rose among younger women aged 20-39 by over 3% annually. The review links rising obesity rates to increased estrogen production by fat cells, driving cancer development. Racial disparities persist, with Black women experiencing mortality rates more than double those of White women despite similar incidence rates.
Detailed Summary
Endometrial cancer represents 95% of uterine cancers and ranks as the fourth most common cancer affecting US women, with projected 68,270 new cases and 14,450 deaths in 2026. This comprehensive JAMA review highlights alarming epidemiological trends that demand attention from both clinicians and public health officials.
The review reveals that US mortality rates from uterine cancer increased 1.6% annually from 2014 to 2023, rising from 4.8 to 5.6 deaths per 100,000 persons. Particularly concerning is the rising incidence among younger women, with annual increases of 3.0% in women aged 20-29 and 3.3% in those aged 30-39 from 2000-2019, despite 80% of cases typically occurring in postmenopausal women.
The authors identify obesity as a key driver, noting that rising obesity rates correlate with increased endometrial cancer incidence from 26.4 per 100,000 in 2013 to 28.8 per 100,000 in 2022. Adipose tissue produces circulating estrogen, which promotes endometrial cancer development through its effects on uterine lining.
Stark racial disparities emerge in outcomes: while age-adjusted incidence rates are similar between Black and White women, mortality rates from 2019-2023 were 18.4 per 100,000 among Black women versus 8.1 per 100,000 among White women. Treatment involves surgery as first-line therapy, with adjuvant radiation or chemotherapy based on staging and molecular subtypes. Five-year survival ranges from over 86% for stage I disease to just 18% for stage IV.
Key Findings
- Endometrial cancer mortality increased 1.6% annually from 2014-2023 in the US
- Incidence rose 3% annually in women aged 20-39, linked to rising obesity rates
- Black women have double the mortality rate of White women despite similar incidence
- Obesity drives cancer through increased estrogen production by adipose tissue
- Five-year survival drops dramatically from 86% (stage I) to 18% (stage IV)
Methodology
This is a comprehensive clinical review article published in JAMA that synthesizes current epidemiological data, treatment guidelines, and survival statistics for endometrial cancer. The review draws from multiple data sources including cancer registries and clinical studies.
Study Limitations
This summary is based solely on the abstract, limiting detailed analysis of methodology and specific data sources. The review nature means it synthesizes existing research rather than presenting new primary data. Full treatment protocols and molecular subtyping details are not available from the abstract alone.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.